Introduction
============

Osteosarcoma (OS) is a common cancerous bone tumor most prevalent in children and young adults ([@b1-ol-0-0-6767]). Specifically, it is a histological form of primary bone cancer derived from primitive transformed cells of mesenchymal origin ([@b2-ol-0-0-6767]). Numerous patients with OS also suffer from panic attacks and swelling of the lower femur or area directly inferior to the knee, and these symptoms are often exacerbated at night ([@b3-ol-0-0-6767]). The cause of OS is unknown; however, it is suggested that this disease may be associated with several factors including inheritance, bone dysplasia, germline *p53* mutations and Rothmund-Thomson syndrome ([@b4-ol-0-0-6767]).

*p53* is a tumor suppressor gene that regulates the expression of apoptosis-associated genes when stimulated by specific molecular signals ([@b5-ol-0-0-6767]). *p53* mutations have been revealed to be associated with the development of OS ([@b6-ol-0-0-6767],[@b7-ol-0-0-6767]). Luo *et al* ([@b8-ol-0-0-6767]) constructed a regulatory network of OS, and further screened *IL-6* and *BCL2L1* as target genes regulated by p53.

U2OS is a commonly utilized OS cell line. Various chemotherapy drugs, including actinomycin D (ActD), doxorubicin (DXR), Nutlin-3 and etoposide (Eto), have been widely used in OS treatment. Among these drugs, ActD ([@b9-ol-0-0-6767]), DXR ([@b10-ol-0-0-6767]) and Eto ([@b11-ol-0-0-6767]) exhibit direct effects on DNA, inhibiting transcription and promoting apoptosis. However, Nutlin-3 interacts with and disrupts mouse double minute 2 homolog (MDM2), a negative regulator of p53. Inhibiting the interaction between MDM2 and p53 results in an increase in activated p53 and therefore apoptosis ([@b12-ol-0-0-6767]). In addition, the four drugs can induce cell cycle arrest ([@b13-ol-0-0-6767]--[@b15-ol-0-0-6767]). The cell-protective agent dimethyl sulfoxide (DMSO) has also been revealed to affect *p53* ([@b16-ol-0-0-6767]).

In order to investigate the response of p53 to the various drugs in the U2OS cell line, p53 chromatin immunoprecipitation combined with sequencing (ChIP-seq) and microarray data of ActD, DXR, Nutlin-3 and Eto treatment were downloaded for analysis of molecular mechanism. Differentially-expressed genes (DEGs) were screened prior to alignment analysis. Finally, the target genes were investigated for the construction of regulatory networks and annotations were processed.

Materials and methods
=====================

### Data sources

The microarray datasets and p53 ChIP-seq datasets of OS cell line U2OS treated with distinct drugs ([@b17-ol-0-0-6767],[@b18-ol-0-0-6767]) were acquired from the Gene Expression Omnibus (GEO; [www.ncbi.nlm.nih.gov/geo](www.ncbi.nlm.nih.gov/geo)) database. The U2OS cell line was treated with various drugs, including DMSO, DXR, ActD, Nutlin-3 and Eto ([Table I](#tI-ol-0-0-6767){ref-type="table"}).

### Analytical methods

*DEG analysis*. The downloaded microarray datasets of ActD and Eto were standardized. Compared with drug treatment groups and the control U2OS cells without any drug treatment, genes with \|log~2~(fold-change)\|\>1 were considered to be DEGs. Raw data from DXR, Nutlin-3 and DMSO microarray datasets were processed by Affy analysis of the Bioconductor 2.0 in R (<http://www.bioconductor.org/packages/release/bioc/html/affy.html>) ([@b19-ol-0-0-6767]) with P\<0.001 and \|log~2~(fold-change)\|\>1 considered to indicate DEGs.

### Alignment and annotation of gene sequences

Bowtie 2 (version 2.0.0-beta5; <http://bowtie-bio.sourceforge.net/bowtie2/index.shtml>) ([@b20-ol-0-0-6767]), a tool for aligning sequencing reads to long reference sequences, was utilized for gene sequence alignment between ChIP-seq and Human Genome hg19. Model-based analysis of ChIP-Seq 2 was applied to identify peaks of transcription factor p53-binding regions ([@b21-ol-0-0-6767]). The two procedures used the default value as parameter. Peak annotations were processed by CisGenome (version 2.0; <http://www.biostat.jhsph.edu/~hji/cisgenome/>) ([@b22-ol-0-0-6767]), an integrated tool for tiling array, ChIP-seq, genome and *cis*-regulatory element analysis. Any genes presenting with a peak located between 2,000 bp upstream and 1,000 bp downstream of the transcription start site was considered to be a p53-binding target gene.

### Screening and annotation of target genes

The data gathered from ChIP-seq and expression profile microarray were combined to further screen p53 target genes in the U2OS cell line (promoter range, 2,000±500 bp; the remaining parameters were set using the default values). Subsequently, a p53-centered expression network was constructed. Finally, the Database for Annotation, Visualization and Integrated Discovery (<http://david.niaid.nih.gov>) ([@b23-ol-0-0-6767]), an analytical tool for extracting biological information from large lists of genes, was used for annotation of target genes.

Results
=======

### Target genes of p53 binding

A total of 212 p53-binding peaks were identified in the untreated group, whereas thousands of peaks were obtained in the treated groups ([Table II](#tII-ol-0-0-6767){ref-type="table"}). Similar numbers of binding sites were identified in the ActD, DXR, Eto and DMSO treatment groups, respectively, with \~1,000 target genes, whereas a total of 5,458 target genes were obtained in the Nutlin-3 treatment group. There were 504 common target genes across the five treatment groups ([Fig. 1](#f1-ol-0-0-6767){ref-type="fig"}). Moreover, these target genes were significantly enriched in GO functions associated with positive regulation of apoptosis, positive regulation of programmed cell death and positive regulation of cell death ([Table III](#tIII-ol-0-0-6767){ref-type="table"}). Notably, programmed cell death can be divided into several categories including type I (apoptosis) and type II (autophagic death) ([@b24-ol-0-0-6767]), thus, target genes enriched in positive regulation of apoptosis were different from those enriched in positive regulation of programmed cell death.

### Distinct responses to various drugs

A total of five DEGs including *AREG, LPP, ATF3, FAM198B* and *HAPLN1* were revealed across each of the five treatment groups ([Fig. 1](#f1-ol-0-0-6767){ref-type="fig"}). Furthermore, a total of 86 common DEGs were obtained from the ActD, DXR, Eto and Nutlin-3 treatment groups, which were classified as Gene Ontology (GO) terms including p53 signaling pathway, cell adhesion and biological adhesion ([Table IV](#tIV-ol-0-0-6767){ref-type="table"}). Several common DEGs including *MDM2, TP53I3, RRM2B, FAS* and *SESN1* identified in these four treatment groups were also target genes for p53 binding ([Table III](#tIII-ol-0-0-6767){ref-type="table"}).

### p53 indirectly regulates downstream genes through other key genes

p53 was able to activate downstream hub genes following a number of drug treatments ([Fig. 2](#f2-ol-0-0-6767){ref-type="fig"}). For example, p53 regulated various genes including *EHF, HOXA10* and *BHLHE40* in the Nutlin-3 treatment group, whereas p53 regulated *EHF, RFX3, TRAF40* and *TCF7L2* in the DXR treatment group. Additionally, p53 was able to indirectly regulate further genes through *TRAF4, BHLHE40* and *HOXA10* hub genes ([Fig. 2](#f2-ol-0-0-6767){ref-type="fig"}).

Discussion
==========

Owing to systemic chemotherapy, long-term outcomes for patients with OS have improved; however, subsequent progress required further research ([@b2-ol-0-0-6767]). In the present study, a total of five DEGs were revealed across all five treatment groups including *AREG, LPP, ATF3, FAM198B* and *HAPLN1*. Additionally, a total of 86 common DEGs were obtained in each of the ActD, DXR, Eto and Nutlin-3 treatment groups, certain of which were identified as being associated with the p53 signaling pathway. Following treatment with various drugs, p53 was identified to be able to activate downstream hub genes including *TRAF4, BHLHE40* and *HOXA10* which was, in turn, able to affect more genes.

DMSO is a cell-protective agent with limited genetic effects. Of the 86 common DEGs obtained in the four other treatment groups (ActD, DXR, Eto and Nutlin-3), only five were affected by DMSO. In the p53 signaling pathway, DEGs including *MDM2, TP53I3* and *RRM2B* were enriched. *MDM2* encodes a nuclear-localized E3 ubiquitin ligase, targets *p53* and further promotes tumor formation ([@b25-ol-0-0-6767]). Soft tissue sarcoma and malignant fibrous histiocytoma are common diseases associated with *MDM2* ([@b26-ol-0-0-6767]). E3 ubiquitin-protein ligase is able to lead to the degradation of p53 by the proteasome and further inhibits cell cycle arrest and apoptosis by binding the transcriptional activation domain ([@b27-ol-0-0-6767]). In addition, *TP53I3* was also differentially expressed in the non-DMSO treatment groups. *TP53I3* is a protein-coding gene which encodes enzymes involved in cellular responses to irradiation and oxidative stress ([@b28-ol-0-0-6767]). This gene is considered to be induced by p53 and involved in p53-mediated cell death ([@b29-ol-0-0-6767]). *TP53I3* is transcriptionally activated by p53 through interacting with downstream pentanucleotide microsatellite sequences, and is associated with the number of pentanucleotide repeats. Furthermore, the microsatellite polymorphism is closely associated with the differential susceptibility to cancer ([@b30-ol-0-0-6767]). Additionally, *RRM2B* encodes the small subunit of p53-incucible ribonucleoside reductase which catalyzes the conversion of ribonucleoside into deoxyribonucleoside diphosphates ([@b31-ol-0-0-6767]). This gene serves a crucial role in cell survival through repairing DNA in a p53-dependent manner ([@b31-ol-0-0-6767]). In the process of cell cycle arrest, *RRM2B* also participates in DNA repair by supplying deoxyribonucleotides ([@b32-ol-0-0-6767]). Therefore, DEGs including *MDM2, TP53I3* and *RRM2B* may be target genes for p53 binding.

In addition to the aforementioned genes, certain downstream genes of p53 may also be affected by drugs. The present study revealed that p53 was able to regulate *EHF* which may in turn regulate further genes in the DMSO, DXR and Nutlin-3 treatment groups. *EHF* encodes a protein that is a member of the E26 transformation-specific transcription factor subfamily ([@b33-ol-0-0-6767]). The encoded protein may participate in carcinogenesis and epithelial differentiation as a transcriptional repressor ([@b34-ol-0-0-6767]). In addition, a previous study has demonstrated that *EHF* may perform roles in molecular processes including sequence-specific DNA-binding transcription factor activity and sequence-specific DNA binding ([@b35-ol-0-0-6767]). Additionally, in the DXR treatment group, p53 was able to regulate hub genes including *RFX3* to further regulate more genes. *RFX3*, a member of the regulatory factor X gene family, encodes a transcriptional activator protein ([@b36-ol-0-0-6767]). This protein is able to bind to DNA with other *RFX* family members ([@b37-ol-0-0-6767]). As with *EHF*, GO annotations associated with *RFK3* exhibited sequence-specific DNA-binding transcription factor activity ([@b38-ol-0-0-6767]). Subsequently, p53 was able to indirectly regulate genes through several hub genes including *EHF* and *RFX* in the U2OS cells treated with a number of drugs.

The results of the present study indicates that p53 is able to directly regulate target genes including *MDM2, TP53I3* and *RRM2B* or indirectly regulate more genes through several hub genes including *EHF* and *RFX* as demonstrated using various treatments of U2OS cells. Furthermore, p53 may be involved in distinct molecular processes regulated by various drug treatments. However, further experimental analysis is required to confirm these results.

![Venn diagram illustrating the number of differentially-expressed gene targets in the DMSO, DXR, Nutlin-3, ActD and Eto treatment groups. ActD, actinomycin D; DMSO, dimethyl sulfoxide; DXR, doxorubicin; Eto, etoposide.](ol-14-04-4694-g00){#f1-ol-0-0-6767}

![Regulatory network of *TP53*. DXR, doxorubicin; DMSO, dimethyl sulfoxide.](ol-14-04-4694-g01){#f2-ol-0-0-6767}

###### 

p53 ChIP combined with sequencing datasets.

  Author             Gene expression omnibus sample   Description of U2OS cells   (Refs)
  ------------------ -------------------------------- --------------------------- ----------------------
  Menendez *et al*     GSM1133482                     DMSO-treated ChIP           ([@b17-ol-0-0-6767])
                       GSM1133483                     DMSO-treated input          
                       GSM1133484                     DXR-treated ChIP            
                       GSM1133485                     DXR-treated input           
                       GSM1133486                     Nutlin-3-treated ChIP       
                       GSM1133487                     Nutlin-3-treated input      
                       GSM1133488                     No treatment ChIP           
                       GSM1133489                     No treatment input          
  Smeenk *et al*     GSM545807                        ActD-treated ChIP           ([@b18-ol-0-0-6767])
                     GSM545808                        Etoposide-treated ChIP      

DMSO, dimethyl sulfoxide; DXR, doxorubicin; ActD, actinomycin D; ChIP, chromatin immunoprecipitation.

###### 

Microarray datasets.

  Author             Gene expression omnibus sample   Description of U2OS cells   (Refs)
  ------------------ -------------------------------- --------------------------- ----------------------
  Menendez *et al*     GSM1131226                     No treatment repeat 1       ([@b17-ol-0-0-6767])
                       GSM1131227                     No treatment repeat 2       
                       GSM1131228                     No treatment repeat 3       
                       GSM1131229                     DXR-treated repeat 1        
                       GSM1131230                     DXR-treated repeat 2        
                       GSM1131231                     DXR-treated repeat 3        
                       GSM1131232                     DMSO-treated repeat 1       
                       GSM1131233                     DMSO-treated repeat 2       
                       GSM1131234                     DMSO-treated repeat 3       
                       GSM1131235                     Nutlin-3-treated repeat 1   
                       GSM1131236                     Nutlin-3-treated repeat 2   
                       GSM1131237                     Nutlin-3-treated repeat 3   
  Smeenk *et al*     GSM552391                        Control ActD repeat 1       ([@b18-ol-0-0-6767])
                     GSM552392                        Control ActD repeat 2       
                     GSM552393                        ActD repeat 1               
                     GSM552394                        ActD repeat 2               
                     GSM552395                        Control Eto repeat 1        
                     GSM552396                        Control Eto repeat 2        
                     GSM552397                        Eto repeat 1                
                     GSM552398                        Eto repeat 2                

DXR, doxorubicin; DMSO, dimethyl sulfoxide; ActD, actinomycin D; Eto, etoposide.

###### 

Gene ontology analysis of p53 target genes.

  Gene ontology number   Role                                           n    Genes                                                                                                                                                                                                                                                                      False discovery rate, ×10^−4^
  ---------------------- ---------------------------------------------- ---- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------
  0043065                Positive regulation of apoptosis               32   *ZAK, IL19, RPS27L, RRM2B*, *BCL2L1*, *SRC, ZC3H8, GPX1, AEN, FAS*, *PHLDA3, FGD3, ARHGEF3, PTPRF*, *HTT, PRKCE, VAV2, TNFSF8*, *PLEKHF1, NOTCH2, CDKN1A*, *TNFRSF10B, NUPR1, BBC3, LYST*, *BAX, FAF1, ABL1, DCUN1D3*, *APBB2, NGF, KALRN*                                 1.92
  0043068                Positive regulation of programmed cell death   32   *ZAK, IL19, RPS27L, RRM2B, BCL2L1*, *SRC, ZC3H8, GPX1, AEN, FAS*, *PHLDA3, FGD3, ARHGEF3*, *PTPRF*, *HTT, PRKCE, VAV2, TNFSF8*, *PLEKHF1, NOTCH2, CDKN1A*, *TNFRSF10B, NUPR1, BBC3*, *LYST, BAX, FAF1, ABL1*, *DCUN1D3*, *APBB2, NGF, KALRN*                               2.24
  0010942                Positive regulation of cell death              32   *ZAK, IL19, RPS27L, RRM2B, BCL2L1*, *SRC, ZC3H8, GPX1, AEN, FAS*, *PHLDA3, FGD3, ARHGEF3, PTPRF*, *HTT, PRKCE, VAV2, TNFSF8*, *PLEKHF1, NOTCH2, CDKN1A*, *TNFRSF10B, NUPR1, BBC3*, *LYST, BAX, FAF1, ABL1*, *DCUN1D3, APBB2, NGF, KALRN*                                   2.48
  0006974                Response to DNA damage stimulus                28   *RAD51C, ZAK, RPS27L, RRM2B*, *SESN1, TRIAP1, RAD51L1, AEN*, *NSMCE2, PHLDA3, FANCC*, *POLH*, *WRN, FOXN3, CDKN1A*, *ATXN3*, *RFC3, EYA2, NUPR1, BTG2*, *BBC3*, *BAX, DDB2, BRE, PCNA*, *ABL1, GADD45A, REV3L*                                                             11.98
  0033554                Cellular response to stress                    35   *RAD51C, ZAK, ADORA2B, RTN4RL1*, *RPS27L, RRM2B, SESN1, GPX1*, *TRIAP1, RAD51L1, AEN, TPO*, *NSMCE2*, *TRPV4, PHLDA3, FANCC*, *POLH, WRN, MAPK10, FOXN3*, *RFC3*, *CDKN1A, ATXN3, EYA2*, *NUPR1*, *BTG2, BBC3, BAX, ATP2A1*, *DDB2*, *BRE*, *PCNA, ABL1, GADD45A, REV3L*   32.40
  0006917                Induction of apoptosis                         24   *ARHGEF3, HTT, IL19, RPS27L*, *RRM2B, VAV2, PRKCE, TNFSF8*, *PLEKHF1, NOTCH2, GPX1*, *CDKN1A, TNFRSF10B, NUPR1*, *BBC3, AEN, BAX, LYST, FAS*, *ABL1, PHLDA3, FGD3, NGF, KALRN*                                                                                             93.17
  0012502                Induction of programmed cell death             24   *ARHGEF3, HTT, IL19, RPS27L*, *RRM2B, VAV2, PRKCE, TNFSF8*, *PLEKHF1, NOTCH2, GPX1*, *CDKN1A, TNFRSF10B, NUPR1*, *BBC3, AEN, BAX, LYST, FAS*, *ABL1, PHLDA3, FGD3, NGF, KALRN*                                                                                             98.13

###### 

Gene ontology and KEGG enrichment analysis of differentially expressed genes in doxorubicin, Nutlin-3, actinomycin D and etoposide treatment groups.

  Gene ontology/KEGG number   Role                                  n     Genes
  --------------------------- ------------------------------------- ----- --------------------------------------------------------------------------------------
  hsa04115                    p53 signaling pathway                   5   *TP53I3, MDM2, RRM2B, FAS, SESN1*
  0007155                     Cell adhesion                         11    *HAPLN1, PVRL4, COL17A1, LPP, PKP4*, *CYFIP2*, *NINJ1*, *KITLG, SLAMF7, NEGR1, FEZ1*
  0022610                     Biological adhesion                   11    *HAPLN1, PVRL4, COL17A1, LPP, PKP4, CYFIP2*, *NINJ1*, *KITLG, SLAMF7, NEGR1, FEZ1*
  0042981                     Regulation of apoptosis               11    *TRIAP1, TP53I3, NUPR1, BTG2, BTG1, RRM2B*, *FAS*, *SLAMF7, NEFL, ANXA4, TP53INP1*
  0043067                     Regulation of programmed cell death   11    *TRIAP1, TP53I3, NUPR1, BTG2, BTG1, RRM2B*, *FAS*, *SLAMF7, NEFL, ANXA4, TP53INP1*
  0010941                     Regulation of cell death              11    *TRIAP1, TP53I3, NUPR1, BTG2, BTG1*, *RRM2B*, *FAS*, *SLAMF7, NEFL, ANXA4, TP53INP1*
  0008083                     Growth factor activity                  5   *TGFA, KITLG, ESM1, AREG, GDF15*

hsa, human (Homo sapiens); KEGG, Kyoto Encyclopedia of Genes and Genomes.
